In this phase 1/2 study, the authors tested the hypothesis that single‐fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach.
Data from this phase 1/2 trial supported an expanded indication for SBRT as first‐line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication. Cancer 2012.
Copyright remains with the authors and publisher.
In this phase 1/2 study, the authors tested the hypothesis that single‐fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach.
Data from this phase 1/2 trial supported an expanded indication for SBRT as first‐line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication. Cancer 2012.
Copyright remains with the authors and publisher.